Answers are grounded in this paper and cite their sources.
Doubling the infliximab dose safely led to remission in patients with Crohn's disease with LOR to 5 mg/kg treatment. Remission was associated with pre-escalation levels of infliximab, interleukin 6, and albumin. Our findings suggest that dose escalation while maintaining a certain level of infliximab is important in achieving remission.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: